Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study

Area of Science:

• Neuroimmunology
• Neurology
• Clinical Trials

Background:

• Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Secondary Progressive Multiple Sclerosis (SPMS) is a phase of MS characterized by continuous neurological deterioration.
• Interferon beta-1b (IFNbeta-1b) is an immunomodulatory therapy used for relapsing forms of MS.

Purpose of the Study:

• To assess the efficacy and safety of interferon beta-1b (IFNbeta-1b) in patients with secondary progressive multiple sclerosis (SPMS).
• To determine if IFNbeta-1b can alter the course of disability progression in SPMS.

Main Methods:

• A 3-year, multicenter, double-blind, placebo-controlled, randomized trial involving 939 subjects with SPMS.
• Participants received either placebo or IFNbeta-1b (250 mcg or 160 mcg/m2) subcutaneously every other day.
• Primary outcome: time to confirmed disability progression (Expanded Disability Status Scale - EDSS). Secondary outcomes: relapse rates, MRI activity, and neuropsychological function.

Main Results:

• No significant difference in time to confirmed EDSS progression between IFNbeta-1b and placebo groups.
• IFNbeta-1b treatment showed significant improvements in reducing clinical relapses and newly active MRI lesions.
• Neutralizing antibodies to IFNbeta-1b were detected but did not consistently impact outcomes; the drug was well-tolerated.

Conclusions:

• Interferon beta-1b did not demonstrate a benefit in slowing disability progression in SPMS.
• Significant benefits were observed in relapse reduction and MRI-measured disease activity.
• These findings align with previous trials, suggesting a specific role for IFNbeta-1b in managing certain aspects of SPMS.